 Matinas BioPharma Holdings, Inc. NYSE AMER: MTNB, today announced that it has initiated the ENHANCE-IT Study Pharmacodynamic Effects of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids to ENHANCE Efficacy in Adults with Hypertriglyceridemia, a head-to-head pharmacodynamic PD study of MAT9001 against Vascepa in patients with elevated triglycerides 150-499 mgdL. The ENHANCE-IT study will assess MAT9001s effectiveness in reducing triglyceride levels and other important lipid markers, as well as gather important data on bioavailability and blood levels of eicosapentaenoic acid EPA and other omega-3 fatty acids. The ENHANCE-IT study is a significant next step in our clinical development program designed to highlight the impressive efficacy of MAT9001 and further distinguish its superior profile from Vascepa, commented James J. Ferguson, M.D., Chief Medical Officer of Matinas. 